Brokerages Set Liquidia Co. (NASDAQ:LQDA) Price Target at $27.13

Shares of Liquidia Co. (NASDAQ:LQDA) have earned a consensus recommendation of “Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $27.13.

LQDA has been the subject of a number of research analyst reports. Raymond James lifted their target price on Liquidia from $27.00 to $29.00 and gave the stock a “strong-buy” rating in a report on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Monday, May 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Liquidia in a report on Monday, May 12th. Finally, Scotiabank reiterated an “outperform” rating on shares of Liquidia in a research note on Monday, May 5th.

Insider Buying and Selling at Liquidia

In other news, insider Jason Adair sold 1,856 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now owns 184,304 shares of the company’s stock, valued at $2,501,005.28. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. The trade was a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,138 shares of company stock valued at $450,233. Insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently modified their holdings of the company. Hurley Capital LLC purchased a new position in shares of Liquidia during the 1st quarter valued at $32,000. GAMMA Investing LLC raised its holdings in Liquidia by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after acquiring an additional 1,173 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in shares of Liquidia in the fourth quarter valued at about $59,000. Quarry LP bought a new position in shares of Liquidia in the first quarter worth about $79,000. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Performance

Shares of LQDA stock opened at $18.88 on Friday. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -11.58 and a beta of 0.24. Liquidia has a one year low of $8.26 and a one year high of $19.41. The company’s 50-day moving average is $14.56 and its 200 day moving average is $13.41.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, research analysts predict that Liquidia will post -1.51 earnings per share for the current fiscal year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).